Mounjaro®
Starting from £179.99/mo
Start journey Learn moreYes, Wegovy can cause vomiting. In the STEP 1 trial, published in the New England Journal of Medicine, around 24% of participants taking semaglutide 2.4mg reported nausea and a notable proportion experienced vomiting — far more than those on placebo. It is one of the most commonly reported side effects, and it tends to be most pronounced in the early weeks of treatment or after a dose increase. That does not mean everyone on Wegovy throws up, or that vomiting means you have to stop. Most people find it eases considerably as the body adjusts. Because Wegovy (semaglutide) is a prescription-only medicine, a prescriber assesses whether it is suitable for you and can guide you through managing side effects should they arise.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The STEP 1 trial remains the foundational evidence for semaglutide 2.4mg used in weight management. Among 1,961 adults without diabetes, gastrointestinal side effects were the most common reason for discontinuation in the active treatment arm. Nausea affected roughly a quarter of participants; vomiting was reported by around 24% on semaglutide versus around 6% on placebo. Those figures sound stark, but the trial also showed that for most participants these effects were mild to moderate and did not persist at the same intensity throughout the 68 weeks. The dose-escalation schedule (starting at 0.25mg and stepping up every four weeks under a prescriber's guidance) was specifically designed to reduce the GI burden. In plain terms: the data confirm that semaglutide can make you throw up, especially early on, but also that the majority of people complete treatment without stopping because of it. The NHS medicines page for semaglutide lists vomiting as a common side effect, meaning it affects between one in ten and one in hundred people across the licensed use of the drug, context worth holding onto.
Semaglutide works as a GLP-1 receptor agonist. GLP-1 is a hormone released after eating; it tells the pancreas to produce insulin, signals fullness to the brain, and slows how quickly food moves from the stomach into the small intestine. That last mechanism, delayed gastric emptying, is the main reason people feel sick or vomit: the stomach is fuller for longer than it would be otherwise, and the brain's nausea centres are more sensitised. Some people find it helps to think of early nausea as evidence the medicine is doing something, even when it is uncomfortable. Eating smaller portions, avoiding very fatty or rich meals, and not lying down immediately after eating all reduce the likelihood of vomiting. A question our prescribers hear regularly is whether Wegovy can cause you to throw up or whether it is simply the body adjusting, and the short answer is that transient vomiting in the first few weeks after starting or after a dose increase is expected; vomiting that is severe, does not settle, or comes with intense abdominal pain is a different matter entirely, and that distinction matters a great deal clinically. Anyone unsure where they sit should contact their prescribing team rather than waiting it out. If you have already experienced this and want to understand what happened, our dedicated page on throwing up with Wegovy covers what people commonly go through and what to do next.
Most GI side effects on Wegovy are self-limiting. Serious presentations are less common but real. Acute pancreatitis is a known, infrequent but potentially serious complication of GLP-1 medicines; the MHRA issued a Drug Safety Update in January 2026 highlighting this. The symptom to watch for is severe, persistent pain in the upper abdomen that radiates toward the back, with or without vomiting. That combination requires emergency medical attention, not a wait-and-see approach. Separately, prolonged vomiting can cause dehydration, which in turn can affect kidney function. If you cannot keep fluids down for more than 24 hours, seek medical help. Gallbladder problems are also reported with semaglutide, sharp pain in the upper right abdomen, especially after eating, combined with vomiting, should be assessed promptly. For anyone who experiences vomiting alongside an allergic reaction (swelling of the face or throat, difficulty breathing), call 999. These scenarios are not designed to alarm; they exist so you know the lines. The practical difference between normal adjustment and something that needs help is usually severity, duration, and whether other symptoms accompany it. Our page on whether vomiting on Wegovy is normal goes deeper on those distinctions.
There is reasonable real-world evidence that simple adjustments cut the frequency and severity of vomiting for most people on semaglutide. Eating slowly, stopping before feeling full, choosing bland lower-fat foods in the early weeks, and staying well hydrated all help. Avoiding alcohol, which amplifies GI irritation, is worth doing. Timing matters too: some people find that taking a dose on a Friday evening means the first 24 hours of any adjustment period falls over the weekend rather than a work morning, others who order on a Monday find the rhythm works differently around their week. There is no universally right day. What matters more is consistency. If vomiting is severe enough to be affecting quality of life, a prescriber can review whether slowing the titration schedule (spending longer at a lower dose) is appropriate. Pausing a dose increase is a recognised clinical option and not a failure. It is also worth knowing that not everyone on semaglutide experiences this to the same degree; individual variation is considerable. If you are considering starting treatment and want to understand what to expect, you can explore the semaglutide overview or look at how Wegovy specifically works. And if cost is a factor in your thinking alongside tolerability, the Wegovy pricing page sets out what is typically involved. Wegovy is a prescription-only medicine; any decision about starting, adjusting or stopping treatment sits with a qualified prescriber, not a checklist.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.